A phase I clinical trial of radiolabeled immunotherapy with humanized LL2 [epratuzumab Y-90] in patients with refractory or recurrent non-Hodgkin's lymphoma
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2008
At a glance
- Drugs Epratuzumab Y-90 (Primary)
- Indications B cell lymphoma
- Focus Adverse reactions
- 08 Jan 2008 Status changed from in progress to discontinued.
- 01 Oct 2005 New trial record.